BIOTECHNOLOGY INNOVATION ORGANIZATION for BIOTECHNOLOGY INNOVATION ORGANIZATION
What was lobbied
17 issue areas, each in the filer's own words, with who lobbied on it and where.
Chemicals/Chemical Industry CHM
Renewable Chemicals/Bio-based Products (Non-Funding) ---Nomenclature Usage ---Pre-market Notification Review ---S. 697: Chemical Safety for the 21st Century Act ---H.R. 2576: TSCA Modernization Act ---S. 1447: Sustainable Chemistry Research and Development Act ---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act Funding for Renewable Chemicals/Bio-based Products ---H.R.2029: Consolidated Appropriations Act for FY 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| TOM DILENGE | — |
| CHARLES H FRITTS | — |
| JEANNE HAGGERTY | — |
| TRACEY LATURNER | — |
| ERICK LUTT | — |
| RINA SINGH | — |
Science/Technology SCI
Synthetic Biology Issue ---H.R. 591: Engineering Biology Research and Development Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| TOM DILENGE | — |
| JEANNE HAGGERTY | — |
| DANA MAURICE O'BRIEN | — |
| RINA SINGH | — |
Animals ANI
Livestock Cloning/Product Labeling ---Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals ---FDA Approval ---Labeling ---One Health Legislation (Senate Discussion Draft) ---H.R.2029: Consolidated Appropriations Act for FY 2016 -------Amendment to Restrict FDA Approval of GE Salmon -------Amendment on GE Salmon Labeling
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN T BAENIG | — |
| JEANNE HAGGERTY | — |
| TRACEY LATURNER | — |
| DANA MAURICE O'BRIEN | — |
| MATTHEW O'MARA | — |
Fuel/Gas/Oil FUE
Biofuels (Non-Funding) ---Accelerated Depreciation Extension ---Climate Change Benefits ---Production Tax Credit Extension ---Implementation of the Agricultural Act of 2014 ---H.R. 2029: Consolidated Appropriations Act of FY 2016 -------Protecting Americans from Tax Hikes (PATH) Act of 2015 Renewable Chemicals/Bio-based Products (Non-Funding) ---Nomenclature Usage ---Pre-market Notification Review ---S. 697: Chemical Safety for the 21st Century Act ---H.R. 2576: TSCA Modernization Act ---S. 1447: Sustainable Chemistry Research and Development Act ---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act Funding for Biomass Crop Assistance Program ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Renewable Chemicals/Bio-based Products ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biofuels ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biorefineries --H.R.2029: Consolidated Appropriations Act for FY 2016 EPA Regulation of Biotechnology ---EPA Points to Consider Guidance Document for GE Algae Renewable Fuel Standard ---Proposed Rule Review of the Federal Coordinated Framework for Biotechnology Products
| Lobbyist | Covered position, as disclosed |
|---|---|
| TOM DILENGE | — |
| CHARLES H FRITTS | — |
| JEANNE HAGGERTY | — |
| TRACEY LATURNER | — |
| ERICK LUTT | — |
| RINA SINGH | — |
Homeland Security HOM
Biodefense Research, Development, and Procurement Issues (Non-funding) Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.R.2029: Consolidated Appropriations Act for FY 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHYLLIS ARTHUR | — |
| KELLY CAPPIO | — |
| JAMIE GREGORIAN | — |
| JEANNE HAGGERTY | — |
| TRACEY LATURNER | — |
| NICK MAGALLANES | — |
| AMY WALKER | — |
Trade (domestic/foreign) TRD
Drug Importation ---H.R.2029: Consolidated Appropriations Act for FY 2016 ---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015 Intellectual Property International Enforcement Foreign Agricultural Biotechnology Laws and Regulations ---Korea Biotechnology Regulations ---Asynchrony of International Approvals ---EU Ag Biotech Policies and Regulations ---China Biotechnology Regulations Biosimilars ---Mexico Biologics Regulations ---Colombia Biologics Regulations TransPacific Partnership ---Sanitary and Phytosanitary Issues ---Data and Intellectual Property Protections for Pharmaceuticals Transatlantic Trade and Investment Partnership ---Intellectual Property Issues ---Reimbursement Transparency
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH DAMOND | — |
| TOM DILENGE | — |
| CHARLES H FRITTS | — |
| JAMIE GREGORIAN | — |
| JEANNE HAGGERTY | — |
| KATHLEEN HOLCOMBE | — |
| NICK MAGALLANES | — |
| MATTHEW O'MARA | — |
| ANNA KATHERINE WEINSTEIN | — |
Agriculture AGR
EPA Regulations on Agricultural Biotechnology ---Pesticide Registration Improvement Act Livestock Cloning/Product Labeling ---Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals ---FDA Approval ---Labeling ---One Health Legislation (Senate Discussion Draft) ---H.R.2029: Consolidated Appropriations Act for FY 2016 -------Amendment to Restrict FDA Approval of GE Salmon -------Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology ---U.S. Government Policy ---H.R. 1599: Safe and Accurate Food Labeling Act of 2015 ---H.R.2029: Consolidated Appropriations Act for FY 2016 Transpacific Partnership ---Sanitary and Phytosanitary Issues Adventitious Presence (Low Level Presence) ---International Low Level Presence Policies Funding for the USDA ---H.R.2029: Consolidated Appropriations Act for FY 2016 Foreign Agricultural Biotechnology Laws and Regulations ---Asynchrony of International Approvals ---China Biotechnology Regulations ---EU Ag-Biotech Policies and Regulations ---Korea Biotechnology Regulations Potential Regulation of New Genetic Modification Technologies Funding for Biomass Crop Assistance Program ---H.R.2029: Consolidated Appropriations Act for FY 2016 USDA/APHIS Agricultural Biotechnology Regulations ---Efficient Science-Based Review of Biotech Products ---Co-existence of Production Systems Review of the Federal Coordinated Framework for Biotechnology Products
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN T BAENIG | — |
| TOM DILENGE | — |
| JEANNE HAGGERTY | — |
| TRACEY LATURNER | — |
| DANA MAURICE O'BRIEN | — |
| MATTHEW O'MARA | — |
Taxation/Internal Revenue Code TAX
Renewable Chemicals/Bio-based Products ---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act Biofuels (Non-Funding) ---Accelerated Depreciation Extension ---Production Tax Credit Extension ---H.R.2029: Consolidated Appropriations Act for FY 2016 ------Protecting Americans from Tax Hikes (PATH) Act of 2015 Research & Development Tax Credit Reforms ---Extension ---Permanency ---Refundable R&D Credit ---H.R.880: To amend the Internal Revenue Code to make permanent the credit for increasing research activities ---S. 537: COMPETE Act ---S. 341: Start-up Jobs and Innovation Act ---H.R.2029: Consolidated Appropriations Act for FY 2016 ------Protecting Americans from Tax Hikes (PATH) Act of 2015 Antibiotic & Diagnostic Tax Credit ---H.R. 3539: Antibiotic & Diagnostic Innovation Act Capital Formation Investment Incentives ---Reform of Capital Gains Rules ---Reform of Net Operating Loss Rules ---Reform of Passive Loss Rules ---S. 537: COMPETE Act ---S. 341: Start-up Jobs and Innovation Act ---H.R. 2179: PARTNER Act Tax Reform ---Innovation Box/Patent Box Orphan Drug Act Tax Credit Controlled Foreign Corporation Look-Through Rule Extension ---H.R.2029: Consolidated Appropriations Act for FY 2016 ------Protecting Americans from Tax Hikes (PATH) Act of 2015 Inversions ---H.R.2029: Consolidated Appropriations Act for FY 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLY CAPPIO | — |
| CHARLES CRAIN | — |
| TOM DILENGE | — |
| ELIZABETH CARTIER ESHAM | — |
| CHARLES H FRITTS | — |
| JEANNE HAGGERTY | — |
| TRACEY LATURNER | — |
| ERICK LUTT | — |
| SHELLY MUI-LIPNIK | — |
| RINA SINGH | — |
Copyright/Patent/Trademark CPT
Patent Reform ---S.1137: The PATENTS Act of 2015 ---H.R. 9: Innovation Act ---Implementation of the America Invents Act of 2011 ---H.R.2029: Consolidated Appropriations Act for FY 2016 Bayh-Dole Act/Tech Transfer ---Commercialization of Federally Funded Research Initiative Intellectual Property International Enforcement Transpacific Partnership ---Data and Intellectual Property Protections for Pharmaceuticals Transatlantic Trade and Investment Partnership ---Intellectual Property Issues Drug Patent Settlements ---S.1137: The PATENTS Act of 2015 ---S. 2019: Preserve Access to Affordable Generics Act of 2015 Inter Partes Review ---Implementation of the American Invents Act of 2011 ---S.1137: The PATENTS Act of 2015 ---H.R. 9: Innovation Act ---H.R.2029: Consolidated Appropriations Act for FY 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH DAMOND | — |
| TOM DILENGE | — |
| CHARLES H FRITTS | — |
| JAMIE GREGORIAN | — |
| JEANNE HAGGERTY | — |
| A. CATHARINE HARRIS | — |
| NICK MAGALLANES | — |
| HANSJORG SAUER | — |
| ANNA KATHERINE WEINSTEIN | — |
Health Issues HCR
Biosimilars ---Biosimilar User Fee Act Implementation ---Coding ---Colombia Biologics Regulations ---Implementation of Affordable Care Act ---Interchangeability and Pharmacy Substitution ---Mexico Biologics Regulations ---Naming Funding for the National Institutes of Health ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Centers for Disease Control and Prevention Vaccine Programs ---H.R.2029: Consolidated Appropriations Act for FY 2016 Vaccine Access/Financing ---Vaccine Injury Compensation Program 340B Drug Pricing Program ---Program Implementation & Oversight ---H.R.2029: Consolidated Appropriations Act for FY 2016 Medicaid Pricing and Rebates ---Implementation of Affordable Care Act ---Average Manufacturer Price Calculations Drug Importation ---H.R.2029: Consolidated Appropriations Act for FY 2016 ---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015 Diagnostics and Personalized Medicine Regulation and Oversight Funding for FDA ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.R.2029: Consolidated Appropriations Act for FY 2016 Biodefense Research, Development, and Procurement Issues TransPacific Partnership ---Data and Intellectual Property Protections for Pharmaceuticals Transatlantic Trade and Investment Partnership ---Intellectual Property Issues ---Reimbursement Transparency Reimbursement for Innovative Products ---Medicare Part B Physician-Administered Products ---Medicare Part D Prescription Drug Program ---Value-based contracting and communications Drug Evaluation and Review ---Compassionate Use/Expanded Access ---FDA Proposed Rule on Changes to Drug Labeling ---Implementation of the FDA Safety and Innovation Act ---Reauthorization of the Prescription Drug User Fee Act ---Special Medical Use/Limited Population Drug Orphan Drug Act Tax Credit Senate Innovation for Healthier Americans ---Biomarkers and Regulatory Science Improvements ---Communication with Healthcare Professionals and Payors ---Expanded Access to Investigational Drugs ---Expedited Pathways ---FDA Hiring Flexibility ---FDA Management and Financial Accountability ---Innovation Incentives ---Longitudinal Study of Chronic Diseases ---Patient Access to Approved Drugs ---Patient-Focused Drug Development ---Use of Real-World Evidence ---Vaccine and Anti-Microbial Resistance Product Development and Incentives ---Generic Entry Incentives Vaccines and Infectious Diseases - General Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative ---H.R.2029: Consolidated Appropriations Act for FY 2016 Government Price Reporting ---H.R.2029: Consolidated Appropriations Act for FY 2016 Gene Editing Technologies ---H.R. 2029: Consolidated Appropriations Act for 2016 Antibiotic & Diagnostic Tax Credit ---H.R. 3539: Antibiotic & Diagnostic Innovation Act Precision Medicine Initiative
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHYLLIS ARTHUR | — |
| KELLY CAPPIO | — |
| CHARLES CRAIN | — |
| JOSEPH DAMOND | — |
| TOM DILENGE | — |
| ELIZABETH CARTIER ESHAM | — |
| CHARLES H FRITTS | — |
| JAMIE GREGORIAN | — |
| JEANNE HAGGERTY | — |
| A. CATHARINE HARRIS | — |
| ERIN ESTEY HERTZOG | — |
| KATHLEEN HOLCOMBE | — |
| TRACEY LATURNER | — |
| NICK MAGALLANES | — |
| SHELLY MUI-LIPNIK | — |
| LAUREL TODD | — |
| AMY WALKER | — |
| ANNA KATHERINE WEINSTEIN | — |
Small Business SMB
Sarbanes Oxley Section 404 (b) ---H.R. 4139: the Fostering Innovation Act Capital Formation Investment Incentives ---Reform of Capital Gains Rules ---Reform of Net Operating Loss Rules ---Reform of Passive Loss Rules ---S. 341: Start-up Jobs and Innovation Act ---S. 537: COMPETE Act ---H.R. 2179: PARTNER Act Reform of SEC Regulation D ---S. 978: the HALOS Act Expansion of Exemption under SEC Regulation A ---H.R. 1839: Reforming Access for Investments in Startup Enterprises (RAISE) Act Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions XBRL Exemption for Small Public Companies ---H.R. 5405: Promoting Job Creation and Reducing Small Business Burdens Act ---H.R. 1965: Small Company Disclosure Simplification Act Capital Market Enhancements ---H.R. 1525: Disclosure Modernization and Simplification Act ---H.R. 1723: Small Company Simple Registration Act ---H.R. 2064: Improving Access to Capital for Emerging Growth Companies Act ---H.R. 4168: Small Business Capital Formation Enhancement Act ---H.R. 3784: Securities & Exchange Commission Small Business Advocate Act -- H.R. 2357: Accelerating Access to Capital Act Proxy Advisory Services ---Impact of Policies on Small Public Companies
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES CRAIN | — |
| TOM DILENGE | — |
| ELIZABETH CARTIER ESHAM | — |
| CHARLES H FRITTS | — |
| JEANNE HAGGERTY | — |
| SHELLY MUI-LIPNIK | — |
Medicare/Medicaid MMM
Medicaid Pricing and Rebates ---Implementation of Affordable Care Act ---Average Manufacturer Price Calculations Reimbursement for Innovative Products ---Medicare Part B Physician-Administered Products ---Medicare Part D Prescription Drug Program ---Value-Based Contracting and Communications Senate Innovation for Healthier Americans Initiative ---Patient Access to Approved Drugs Government Price Reporting ---H.R.2029: Consolidated Appropriations Act for FY 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| TOM DILENGE | — |
| JAMIE GREGORIAN | — |
| JEANNE HAGGERTY | — |
| A. CATHARINE HARRIS | — |
| ERIN ESTEY HERTZOG | — |
| KATHLEEN HOLCOMBE | — |
| TRACEY LATURNER | — |
| NICK MAGALLANES | — |
| LAUREL TODD | — |
Medical/Disease Research/Clinical Labs MED
Funding for National Institutes of Health ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.R.2029: Consolidated Appropriations Act for FY 2016 Biodefense Research, Development, and Procurement Issues (Non-funding) Senate Innovation for Healthier Americans Initiative ---Longitudinal Study of Chronic Diseases Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative ---H.R.2029: Consolidated Appropriations Act for FY 2016 Gene Editing Technologies ---H.R. 2029: Consolidated Appropriations Act for 2016 Precision Medicine Initiative
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHYLLIS ARTHUR | — |
| KELLY CAPPIO | — |
| TOM DILENGE | — |
| ELIZABETH CARTIER ESHAM | — |
| JAMIE GREGORIAN | — |
| JEANNE HAGGERTY | — |
| KATHLEEN HOLCOMBE | — |
| TRACEY LATURNER | — |
| NICK MAGALLANES | — |
| AMY WALKER | — |
Budget/Appropriations BUD
Funding for the USDA ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for FDA ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Centers for Disease Control and Prevention Vaccine Programs ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for the National Institutes of Health ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biomass Crop Assistance Program ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Renewable Chemicals/Bio-based Products ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biofuels ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biorefineries ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative ---H.R.2029: Consolidated Appropriations Act for FY 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHYLLIS ARTHUR | — |
| BRIAN T BAENIG | — |
| KELLY CAPPIO | — |
| KATHLEEN HOLCOMBE | — |
| TRACEY LATURNER | — |
| ERICK LUTT | — |
| NICK MAGALLANES | — |
| AMY WALKER | — |
| ANNA KATHERINE WEINSTEIN | — |
Consumer Issues/Safety/Products CSP
Livestock Cloning/Product Labeling ---Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals ---FDA Approval ---Labeling ---One Health Legislation (Senate Discussion Draft) ---H.R.2029: Consolidated Appropriations Act for FY 2016 -------Amendment to Restrict FDA Approval of GE Salmon -------Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology ---U.S. Government Policy ---H.R. 1599: Safe and Accurate Food Labeling Act of 2015 ---H.R.2029: Consolidated Appropriations Act for FY 2016 Biosimilars ---Colombia Biologics Regulations ---Mexico Biologics Regulations ---Implementation of Affordable Care Act ---Interchangeability and Pharmacy Substitution ---Naming USDA/APHIS Agricultural Biotechnology Regulations ---Efficient Science-Based Review of Biotech Products ---Co-existence of Production Systems Drug Importation ---H.R.2029: Consolidated Appropriations Act for FY 2016 ---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN T BAENIG | — |
| TOM DILENGE | — |
| JEANNE HAGGERTY | — |
| ERIN ESTEY HERTZOG | — |
| KATHLEEN HOLCOMBE | — |
| TRACEY LATURNER | — |
| NICK MAGALLANES | — |
| DANA MAURICE O'BRIEN | — |
| ANNA KATHERINE WEINSTEIN | — |
Energy/Nuclear ENG
Biofuels (Non-Funding) ---Accelerated Depreciation Extension ---Climate Change Benefits ---Production Tax Credit Extension ---Implementation of the Agricultural Act of 2014 ---H.R. 2029: Consolidated Appropriations Act of FY 2016 -------Protecting Americans from Tax Hikes (PATH) Act of 2015 Renewable Chemicals/Bio-based Products (Non-Funding) ---Nomenclature Usage ---Pre-market Notification Review ---S. 697: Chemical Safety for the 21st Century Act ---H.R. 2576: TSCA Modernization Act ---S. 1447: Sustainable Chemistry Research and Development Act ---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act Funding for Biomass Crop Assistance Program ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Renewable Chemicals/Bio-based Products ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biofuels ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biorefineries --H.R.2029: Consolidated Appropriations Act for FY 2016 EPA Regulation of Biotechnology ---EPA Points to Consider Guidance Document for GE Algae Renewable Fuel Standard ---Proposed Rule Review of the Federal Coordinated Framework for Biotechnology Products
| Lobbyist | Covered position, as disclosed |
|---|---|
| TOM DILENGE | — |
| CHARLES H FRITTS | — |
| JEANNE HAGGERTY | — |
| TRACEY LATURNER | — |
| ERICK LUTT | — |
| DANA MAURICE O'BRIEN | — |
| RINA SINGH | — |
Food Industry (safety, labeling, etc.) FOO
Livestock Cloning/Product Labeling ---Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals ---FDA Approval ---Labeling ---One Health Legislation ---H.R.2029: Consolidated Appropriations Act for FY 2016 ------Amendment to Restrict FDA Approval of GE Salmon ------Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology ---U.S. Government Policy ---H.R. 1599: Safe and Accurate Food Labeling Act of 2015 ---H.R.2029: Consolidated Appropriations Act for FY 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN T BAENIG | — |
| TOM DILENGE | — |
| JEANNE HAGGERTY | — |
| TRACEY LATURNER | — |
| DANA MAURICE O'BRIEN | — |
| MATTHEW O'MARA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.